001     273946
005     20250127091353.0
024 7 _ |a pmc:PMC11638412
|2 pmc
024 7 _ |a 10.1007/s00415-024-12829-9
|2 doi
024 7 _ |a pmid:39666145
|2 pmid
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2024-01420
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Elter, Tim-Lukas
|0 P:(DE-2719)9001258
|b 0
|e First author
|u dzne
245 _ _ |a Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736935987_31493
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Knowledge about the distribution and frequency of the respective haplotypes on the wildtype and mutant allele is highly relevant in the context of future gene therapy clinical studies in Spinocerebellar Ataxia Type 3, the most common autosomal dominantly inherited ataxia. Single nucleotide polymorphisms associated to the disease-causing gene, ATXN3, have been determined. We wanted to investigate the frequency and regional distribution of two intragenic single nucleotide polymorphisms (SNPs) in a large European SCA3 cohort and their relation to the clinical phenotype.The genotypes of the two polymorphisms at base pair positions 987 and 1118 of the ATXN3 were determined for their co-localization on the normal and expanded allele, respectively, in 286 SCA3 mutation carriers and 117 healthy controls from 11 European sites.The distribution of genotypes on the expanded allele differed from those of the wildtype allele of SCA3 mutation carriers and of healthy controls, and was mainly influenced by the regional origin. In our cohort, no particular clinical phenotype was associated with any specific haplotype.Our results confirm distinct allocations of SNPs associated to the expanded ATXN3, and accordingly the consideration of allele-specific therapies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ATXN3
|2 Other
650 _ 7 |a ASO
|2 Other
650 _ 7 |a Polymorphism
|2 Other
650 _ 7 |a SCA3
|2 Other
650 _ 7 |a SNP
|2 Other
650 _ 7 |a Spinocerebellar ataxia
|2 Other
650 _ 7 |a Ataxin-3
|0 EC 3.4.19.12
|2 NLM Chemicals
650 _ 7 |a ATXN3 protein, human
|0 EC 3.4.19.12
|2 NLM Chemicals
650 _ 7 |a Nerve Tissue Proteins
|2 NLM Chemicals
650 _ 7 |a Repressor Proteins
|2 NLM Chemicals
650 _ 7 |a Nuclear Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Ataxin-3: genetics
|2 MeSH
650 _ 2 |a Polymorphism, Single Nucleotide
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Nerve Tissue Proteins: genetics
|2 MeSH
650 _ 2 |a Repressor Proteins: genetics
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Nuclear Proteins: genetics
|2 MeSH
650 _ 2 |a Gene Frequency
|2 MeSH
650 _ 2 |a Haplotypes
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Sturm, Daniel
|b 1
700 1 _ |a Santana, Magda M
|0 0000-0003-4076-7516
|b 2
700 1 _ |a Schaprian, Tamara
|0 P:(DE-2719)2812594
|b 3
|u dzne
700 1 _ |a Raposo, Mafalda
|0 0000-0001-6899-0352
|b 4
700 1 _ |a Melo, Ana Rosa Vieira
|0 0000-0002-1759-762X
|b 5
700 1 _ |a Lima, Manuela
|0 0000-0002-3357-3273
|b 6
700 1 _ |a Koyak, Berkan
|0 P:(DE-2719)9001550
|b 7
|u dzne
700 1 _ |a Oender, Demet
|0 P:(DE-2719)9000685
|b 8
|u dzne
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 9
|u dzne
700 1 _ |a Lopes, Sara
|b 10
700 1 _ |a Silva, Patrick
|0 0000-0002-5436-8949
|b 11
700 1 _ |a de Almeida, Luís Pereira
|0 0000-0001-5831-3307
|b 12
700 1 _ |a Giunti, Paola
|0 0000-0003-3508-4788
|b 13
700 1 _ |a Garcia-Moreno, Hector
|b 14
700 1 _ |a Nethisinhe, Suran
|b 15
700 1 _ |a de Vries, Jeroen
|b 16
700 1 _ |a van de Warrenburg, Bart P
|b 17
700 1 _ |a van Gaalen, Judith
|b 18
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 19
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 20
|u dzne
700 1 _ |a Reetz, Kathrin
|0 0000-0002-9730-9228
|b 21
700 1 _ |a Erdlenbruch, Friedrich
|b 22
700 1 _ |a Jacobi, Heike
|b 23
700 1 _ |a Infante, Jon
|b 24
700 1 _ |a Riess, Olaf
|0 0000-0002-7011-1369
|b 25
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 26
|u dzne
700 1 _ |a group, ESMI study
|b 27
|e Collaboration Author
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 28
|e Last author
700 1 _ |a Hübener-Schmid, Jeannette
|0 0000-0002-4973-0923
|b 29
700 1 _ |a Timmann, Dagmar
|b 30
|e Contributor
700 1 _ |a Thieme, Andreas
|b 31
|e Contributor
773 _ _ |a 10.1007/s00415-024-12829-9
|g Vol. 272, no. 1, p. 54
|0 PERI:(DE-600)1421299-7
|n 1
|p 54
|t Journal of neurology
|v 272
|y 2025
|x 0367-004X
856 4 _ |u https://pub.dzne.de/record/273946/files/DZNE-2024-01420%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/273946/files/DZNE-2024-01420.pdf
856 4 _ |u https://pub.dzne.de/record/273946/files/DZNE-2024-01420%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/273946/files/DZNE-2024-01420%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/273946/files/DZNE-2024-01420%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/273946/files/DZNE-2024-01420.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:273946
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001258
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2812594
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001550
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9000685
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001510
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2811275
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811327
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 1
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21